Medicinal chemistry expertise combined with an industry track record in the development of muscarinic agonists

• Validated mechanism: M1 muscarinic receptor agonism has emerged as an important mechanism for schizophrenia and psychosis.

• Lead candidate AVB-08 is a highly potent M1 agonist (IC50 ~1 nM) with improved selectivity (>1000 -fold margin over M2-M5) - optimized for brain penetration and once-daily dosing.

• Unique expertise: Management with years of experience with development of muscarinics, biopharma operations, taking companies from academia to exit.

• Clinical development: Rapid onset of action. Clear path to clinical PoC, pivotal trials <2 mo in duration.

• Commercial opportunity: Very large market opportunity in schizophrenia and dementia-related psychosis.

• Other opportunities: Potential for multiple high-value indications such as Alzheimer’s and neuropathic pain